MS-180 is a novel orally active GPIIb-IIIa antagonist that demonstrates dose-dependent inhibition of platelet aggregation in preclinical models, supporting its potential for clinical evaluation.
No takes yet. Share an insight, caveat, or question.
Provides preclinical support for oral GPIIb-IIIa antagonists; leaves open translation to human efficacy and safety.
Okumura et al. (1998) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: